Eaton Vance Management Alnylam Pharmaceuticals, Inc. Transaction History

Eaton Vance Management

$67.5 Billion
Q3 2022

A detailed history of Eaton Vance Management transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Eaton Vance Management holds 307,288 shares of ALNY stock, worth $140 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

307,288

Previous 306,751 0.18%

Holding current value

$140 Million

Previous $44.7 Million 37.48%

% of portfolio

0.09%

Previous 0.06%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $74,395 - $124,584	537 Added 0.18%	307,288 $61.5 Million
Q2 2022 Aug 15, 2022	BUY	$120.42 - $169.29 $62,979 - $88,538	523 Added 0.17%	306,751 $44.7 Million
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $33.4 Million - $45.7 Million	262,893 Added 606.65%	306,228 $50 Million
Q4 2021 Feb 14, 2022	SELL	$159.56 - $209.29 $107,543 - $141,061	-674 Reduced 1.53%	43,335 $7.31 Million
Q3 2021 Nov 15, 2021	BUY	$169.75 - $207.73 $427,430 - $523,064	2,518 Added 6.07%	44,009 $8.29 Million
Q2 2021 Aug 16, 2021	SELL	$128.63 - $176.89 $563,142 - $774,424	-4,378 Reduced 9.54%	41,491 $7.03 Million
Q1 2021 May 17, 2021	SELL	$126.83 - $175.69 $13.2 Million - $18.2 Million	-103,799 Reduced 69.35%	45,869 $6.48 Million
Q4 2020 Feb 12, 2021	SELL	$122.97 - $147.0 $7.91 Million - $9.45 Million	-64,315 Reduced 30.06%	149,668 $19.5 Million
Q3 2020 Nov 13, 2020	SELL	$121.19 - $165.49 $817,184 - $1.12 Million	-6,743 Reduced 3.05%	213,983 $31.2 Million
Q2 2020 Aug 13, 2020	BUY	$104.21 - $156.44 $11,671 - $17,521	112 Added 0.05%	220,726 $32.7 Million
Q1 2020 May 14, 2020	BUY	$93.12 - $133.99 $3,166 - $4,555	34 Added 0.02%	220,614 $24 Million
Q4 2019 Feb 11, 2020	SELL	$74.51 - $124.23 $1,788 - $2,981	-24 Reduced 0.01%	220,580 $25.4 Million
Q2 2019 Aug 16, 2019	SELL	$65.86 - $92.79 $8.64 Million - $12.2 Million	-131,129 Reduced 37.28%	220,604 $16 Million
Q1 2019 May 14, 2019	BUY	$72.76 - $93.45 $22.8 Million - $29.3 Million	313,942 Added 830.73%	351,733 $32.9 Million
Q2 2018 Aug 10, 2018	BUY	$88.31 - $107.8 $86,102 - $105,105	975 Added 2.65%	37,791 $3.72 Million
Q1 2018 May 07, 2018	SELL	$115.92 - $148.54 $5,796 - $7,427	-50 Reduced 0.14%	36,816 $4.39 Million
Q4 2017 Feb 12, 2018	BUY	$114.49 - $139.98 $572,450 - $699,900	5,000 Added 15.69%	36,866 $4.68 Million
Q3 2017 Nov 13, 2017	BUY	$72.53 - $118.27 $2.31 Million - $3.77 Million	31,866	31,866 $3.74 Million

Others Institutions Holding ALNY

# of Institutions

808

Shares Held

115M

Call Options Held

584K

Put Options Held

648K

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $56.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

News

Stay updated on Eaton Vance Management with notifications on news.

Account

Eaton Vance Management Alnylam Pharmaceuticals, Inc. Transaction History